We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomarker Based Non-Endoscopic Technology Identifies Risk for Esophageal Cancer

By HospiMedica International staff writers
Posted on 23 May 2022
Print article
Image: EsoGuard has demonstrated over 90% specificity and 90% sensitivity in identifying Barrett’s Esophagus (Photo courtesy of Lucid Diagnostics)
Image: EsoGuard has demonstrated over 90% specificity and 90% sensitivity in identifying Barrett’s Esophagus (Photo courtesy of Lucid Diagnostics)

Barrett's esophagus (BE) is the benign and treatable precursor condition to esophageal adenocarcinomas (EAC) which is usually diagnosed at an advanced stage and is difficult to treat. Finding BE, a sign of risk, could help patients by giving physicians a chance to intervene early. A significant percentage of people who have chronic gastro-esophageal reflux disease, more commonly known as GERD, are at most risk for Barrett's esophagus. Those with chronic GERD are recommended to have an endoscopy to check for pathologic features of the condition. Endoscopy is an invasive procedure requiring sedation and a loss of a day at work for the patient and the necessary companion. After diagnosis, patients are followed longitudinally with more endoscopic exams and at the first signs of the condition worsening, the affected tissues can be removed to prevent the development of cancer. Now, a new technology coupled with a new biomarker test are giving patients timely access to a quick, accurate and less invasive way to identify risk for BE.

Lucid Diagnostics Inc.’s (New York, NY, USA) EsoGuard Esophageal DNA Test, performed on samples collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy. The Esocheck cell collection device consists of a capsule containing a small balloon with a textured surface to enhance cell collection. EsoCheck is provided in a kit with the balloon and capsule attached to a 68 cm catheter with 5 cm markings to indicate to the operator when the capsule is in the stomach and when the targeted region of the esophagus has been traversed by sampling balloon, as well as two balloon inflation syringes.

EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. It quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1). Custom proprietary software, incorporating advanced genetic informatics, uses an advanced algorithm to convert the DNA sequence at the target sites into a binary clinical result. EsoGuard assesses the presence of methylation in targeted regions of the Vimentin and CCNA1 genes after the specimens have undergone bisulfite conversion - a chemical step which allows characterization of DNA methylation at CpG sites. EsoGuard is used to detect non-dysplastic Barrett’s Esophagus including short segment and long segment, dysplastic BE including both low and high grade forms, adenocarcinoma of the esophagus including intramucosal, or adenocarcinoma of the gastroesophageal junction. A recent landmark study compared esophageal brushings tested with EsoGuard, with esophageal tissue biopsies, evaluated with conventional histopathology in 322 patients with and without BE. EsoGuard was shown to have greater than 90% specificity and sensitivity at detecting non-dysplatic BE in these patients.

Related Links:
Lucid Diagnostics Inc. 


Print article

Channels

AI

view channel
Image: ‘Hologram patients’ developed to help train doctors and nurses (Photo courtesy of University of Cambridge)

Life-Like Hologram Patients Train Doctors for Real-Time Decision Making in Emergencies

A medical training project using 'mixed reality' technology aims to make consistent, high-level and relevant clinical training more accessible across the world. University of Cambridge (Cambridge, UK)... Read more

Surgical Techniques

view channel
Image: The Senhance surgical system with digital laparoscopy (Photo courtesy of Asensus Surgical)

Digital Laparoscopic Platform Leverages Augmented Intelligence and Machine Learning

Challenges in laparoscopic surgery can impact cost, utilization, effectiveness, and outcomes of the procedure. For instance, the inability of the surgeon to control vision can create efficiency and safety... Read more

Patient Care

view channel
Image: The biomolecular film can be picked up with tweezers and placed onto a wound (Photo courtesy of TUM)

Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients

Conventional bandages may be very effective for treating smaller skin abrasions, but things get more difficult when it comes to soft-tissue injuries such as on the tongue or on sensitive surfaces like... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more

Business

view channel
Image: Expanding the role of autonomous robots can mitigate the shortage of physicians (Photo courtesy of Pexels)

Robot-Assisted Surgical Devices Market Driven by Increased Demand for Patient-Specific Surgeries

An aging population and accompanying retirements will cause a significant physician shortfall of 55,000 to 150,000 by 2030, creating a gap in the healthcare system. Expanding the role of autonomous robots... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.